ALSO NOTED: GSK to co-develop cancer therapy; Singulair approved for new use; Teva gets FDA nod; and much more...

> GlaxoSmithKline has exercised an option to help develop and market a new cancer therapy with Human Genome Sciences. Story [1]

> The FDA has approved Merck's Singulair for indoor allergy uses. Release [2]

> The FDA has given tentative approval to Teva's ANDA for Granisetron HCl Injection, 1 mg/mL single dose vials and Granisetron HCl Injection, 4 mg/4mL in multi-dose vials. Story [3]

> The National Cancer Institute says that an ambitious program of earlier detection, better therapies and controls on tobacco can stop lung cancer by 2015. Report [4]

> Dyax and Merck have inked a licensing deal for the discovery of therapeutic antibodies and peptides. Release [5]

> Novartis has signed an agreement with SeBo of Germany to acquire the global rights for a novel oral phosphate binder in development for the treatment of elevated serum phosphate levels in late- or end-stage renal disease patients. Release [6]

And Finally… The death rate from heart disease in New York is among the highest in the country, but health officials are at a loss to explain why. Article [7]